To broaden innovation base in cell and gene therapy Bayer AG has acquired Asklepios BioPharmaceutical, Inc. (AskBio) for approximately $2 billion. The deal helps to meet urgently needed cell and gene therapy treatments to patients across multiple disease areas.
- AskBio’s industry leading AAV-based gene therapy platform already yielding commercial and clinical stage assets with potential of helping larger patient populations
- BioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas.
The prominent collaborations and supports by Bayer are featured below:
Sep 2020: Bayer, announced that it had completed the acquisition of UK-based biotech company KaNDy Therapeutics Ltd. for approximately $425 million. The deal will expand Bayers drug development pipeline in women’s healthcare.
Aug 2020: Bayer along with a US-based digital health company Informed Data Systems Inc. (One Drop), to jointly develop digital health products for multiple therapeutic areas.
May 2020: Bayer amid COVID-19 pandemic announced that it support for a new, multi-year Harvard Data Science Initiative (HDSI) research effort. The new research helps to understand how to build confidence in the reliability, capability and integrity of scientific data and sound science.
April 2020: The leading life sciences company Bayer has announced an approximately $1.2 billion donation to support Brazils fight against COVID-19. The fund contributed to the Brazilian governments Solidaric Fundraising campaign to finance various projects for the prevention, diagnosis and treatment of COVID-19.
April 2020: WuXi Biologics a leading technology platform for drug development, had announced the completion of acquisition of a drug product manufacturing plant in Leverkusen, Germany from Bayer. WuXi Biologics as per acquisition agreement has taken over the plant operations, purchased plant equipment and signed a long-term building lease contract.
March 2020, Bayer announced a research collaboration and license agreement with Curadev Pvt. Ltd., a drug discovery company based in India, for Curadevs Stimulator of Interferon Genes (STING) antagonist program. The collaboration aims to discover new drug candidates for the treatment of lung diseases, cardiovascular diseases and other inflammatory diseases. STING antagonists offer tremendous potential for new treatments as STING is known to play a role in activating the innate immune system in auto-inflammatory diseases.
Bayer, headquartered in Leverkusen, Germany, is global pharmaceutical and life sciences company. The company has core competencies in the life science fields of health care and nutrition. The company has employed approximately 104,000 people worldwide. Bayer brand stands for trust, reliability and quality across the globe.